Compounds > marcellomycin
Page last updated: 2024-11-07

marcellomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Marcellomycin is a potent antibiotic produced by the bacterium *Streptomyces marcellus*. It exhibits broad-spectrum activity against various bacterial species, including methicillin-resistant *Staphylococcus aureus* (MRSA). Marcellomycin is a complex molecule with a unique chemical structure. Its biosynthesis involves a series of enzymatic steps that are poorly understood. The compound's interesting biological activity has led to extensive research efforts aimed at understanding its mechanism of action and its potential therapeutic applications. Researchers are particularly interested in its ability to inhibit bacterial protein synthesis and its potential to overcome antibiotic resistance mechanisms. Despite its promising properties, marcellomycin is not currently used in clinical settings. However, its unique structure and potent antibacterial activity make it an attractive target for drug development. Further research is ongoing to explore its potential as a lead compound for the development of new antibiotics.'

marcellomycin: pyrromycinone glycoside antibiotic isolated from bohemic acid complex; RN given refers to parent cpd(1R-(1alpha,2beta,4beta))-isomer; structure in fourth source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107861
CHEMBL ID508628
MeSH IDM0064513

Synonyms (16)

Synonym
marcellomycin
nsc 265211
nsc-265211
rhodirubin e
63710-10-1
1-naphthacenecarboxylic acid, 4-((o-2,6-dideoxy-alpha-l-lyxo-hexopyranosyl-(1-4)-o-2,6-dideoxy-alpha-l-lyxo-hexopyranosyl-(1-4)-2,3,6-trideoxy-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-diox
ccris 2263
antibiotic ma 144u2
CHEMBL508628
methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat
unii-3296x8l13e
3296x8l13e ,
VJRAUFKOOPNFIQ-TVEKBUMESA-N
antibiotic ma-144u2
Q27256169
DTXSID101031625

Research Excerpts

Overview

Marcellomycin is a strong inhibitor of the Escherichia coli RNA polymerase-catalyzed synthesis of RNA from the strong A promoters of bacteriophage T7 DNA.

ExcerptReferenceRelevance
"Marcellomycin is a new anthracycline that was proposed for clinical trials on the basis of experimental data suggesting reduced potential for hematologic and cardiac toxicity as compared to conventional anthracyclines. "( Clinical phase I trial of marcellomycin with a single-dose schedule.
Crespeigne, N; de Marneffe, M; Dodion, P; Kenis, Y; Lenaz, L; Nicaise, C; Piccart, M; Rozencweig, M; Sculier, JP, 1983)		2.01
"Marcellomycin is a strong inhibitor of the Escherichia coli RNA polymerase-catalyzed synthesis of RNA from the strong A promoters of bacteriophage T7 DNA. "( Inhibition of the RNA polymerase-catalyzed synthesis of RNA by marcellomycin. Preferential interference of the inhibitor with the stabilization of the ternary promoter-RNA polymerase-nascent RNA complex.
Aktipis, S; Kriebardis, T, 1988)		1.96

Pharmacokinetics

ExcerptReferenceRelevance
" The peak concentrations of the metabolites were 25% or less or the peak concentration for MCM, but their persistence resulted in higher AUCs than that for MCM."( Human pharmacokinetics of marcellomycin.
Bachur, NR; Dodion, P; Nicaise, C; Riggs, CE; Rozencweig, M; Tamburini, JM; Watthieu, M, 1985)		0.57

Dosage Studied

ExcerptRelevanceReference
" MCM was infused IV over 15 min at a dosage of 27."( Human pharmacokinetics of marcellomycin.
Bachur, NR; Dodion, P; Nicaise, C; Riggs, CE; Rozencweig, M; Tamburini, JM; Watthieu, M, 1985)		0.57
" At that dosage level, aclacinomycin A also induced differentiation, while doxorubicin was ineffective, a finding consistent with the effects of these anthracyclines on HL-60 cells in suspension culture."( Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
Brown, BJ; Marsh, JC; Nierenburg, M; Sartorelli, AC; Schwartz, EL, 1983)		0.27
" Colony-forming cells from mice, dogs, and humans were all found to have exponential dose-response curves for the agents studied, with variation of the slopes between species and agents."( Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Brown, BJ; Marsh, JC; Nierenburg, MM, 1983)		0.48
" Patients were treated at 6 dosage levels ranging from 5 to 30 mg/m2 weekly for 4 weeks."( A phase I trial of marcellomycin with a weekly dose schedule.
Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Kaplan, S; Varini, M, 1983)		0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID332746Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 0.8 mg/kg, ip single dose on day 1
AID332744Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 3.2 mg/kg, ip single dose on day 1
AID332720Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 0.4 mg/kg, ip single dose on day 1
AID332730Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 6.4 mg/kg, ip single dose on day 1 relative to control
AID332718Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 1.6 mg/kg, ip single dose on day 1
AID332742Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 12.8 mg/kg, ip single dose on day 1
AID332761Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as survivors on day 5 at 0.4 mg/kg, ip single dose on day 1
AID332731Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 3.2 mg/kg, ip single dose on day 1 relative to control
AID332748Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 0.2 mg/kg, ip single dose on day 1
AID332716Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 6.4 mg/kg, ip single dose on day 1
AID332769Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as median survival time at 25.6 mg/kg, ip single dose on day 1
AID333959Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 12.8 mg/kg, ip single dose on day 1
AID332733Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 0.8 mg/kg, ip single dose on day 1 relative to control
AID332758Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as survivors on day 5 at 3.2 mg/kg, ip single dose on day 1
AID332735Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 0.2 mg/kg, ip single dose on day 1 relative to control
AID332717Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 3.2 mg/kg, ip single dose on day 1
AID332770Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 0.2 mg/kg, ip qd for 1 to 5 days relative to control
AID332734Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 0.4 mg/kg, ip single dose on day 1 relative to control
AID332729Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 12.8 mg/kg, ip single dose on day 1 relative to control
AID332721Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 0.2 mg/kg, ip single dose on day 1
AID332759Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as survivors on day 5 at 1.6 mg/kg, ip single dose on day 1
AID332719Antitumor activity against mouse L1210 cells implanted in CDF1 mouse assessed as median survival time at 0.8 mg/kg, ip single dose on day 1
AID332760Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as survivors on day 5 at 0.8 mg/kg, ip single dose on day 1
AID332743Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 6.4 mg/kg, ip single dose on day 1
AID332745Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 1.6 mg/kg, ip single dose on day 1
AID332757Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as survivors on day 5 at 6.4 mg/kg, ip single dose on day 1
AID332732Antitumor activity against mouse L1210 cells implanted in CDF1 mouse at 1.6 mg/kg, ip single dose on day 1 relative to control
AID332747Toxicity in mouse L1210 cells implanted CDF1 mouse assessed as average weight gain at 0.4 mg/kg, ip single dose on day 1
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (92.31)18.7374
1990's2 (7.69)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.99 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (12.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		2.3720sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		3.0610acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		3.0610alpha-amino acid;
fluoroamino acid		trypanocidal drug
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		3.4720dihydroxyanthraquinoneanalgesic;
antineoplastic agent
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		1.9710amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		3.0610non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
mannose
mannopyranose : The pyranose form of mannose.		1.9710D-aldohexose;
D-mannose;
mannopyranose		metabolite
showdomycin
Showdomycin: 3-beta-D-Ribofuranosylmaleimide. Antineoplastic antibiotic isolated from Streptomyces showdoensis. It is possibly active also as a sulfhydryl reagent.		3.0610
1-deoxynojirimycin
1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.		3.06102-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid		anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		4.3160aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		1.9610
ribavirin
Rebetron: Rebetron is tradename		3.06101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		3.0610aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
diaziquone
diaziquone: RN given refers to parent cpd. diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.		3.06101,4-benzoquinones;
aziridines;
carbamate ester;
enamine		alkylating agent;
antineoplastic agent
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		3.0610anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
n,n-dimethyldoxorubicin
N,N-dimethyldoxorubicin: RN given refers to parent cpd(8S-cis)-isomer		1.9710
aclacinomycin
aklavin: antibiotic prepared from culture liquids of streptomycete (A 1129); possessing antiphage activity; structure. aclacinomycin T : An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage.		3.9740aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion		antimicrobial agent;
antineoplastic agent;
metabolite
pyrromycin
[no description available]		2.3720anthracycline
carboplatin
[no description available]		3.0610
glucosamine
D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.		3.0610D-glucosamineEscherichia coli metabolite;
geroprotector;
mouse metabolite
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		3.0610cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
aclarubicin
Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.		5.08140aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
valrubicin
[no description available]		1.9510anthracycline;
trifluoroacetamide
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		3.06101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
n,n-dimethyldaunorubicin
N,N-dimethyldaunorubicin: RN given refers to (8S-cis)-isomer		1.9710
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		3.47202-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
nadp
[no description available]		1.9710
n,n-dibenzyldaunorubicin
N,N-dibenzyldaunorubicin: RN given refers to (arabino-(8S-cis))-isomer; structure		6.9610
esorubicin
esorubicin: RN given refers to parent cpd; synthesized deriv of doxorubicin		3.0610
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9710organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
carboxyphthalato-1,2-diaminocyclohexaneplatinum
carboxyphthalato-1,2-diaminocyclohexaneplatinum: RN given refers to hydrogen(SP-4-3(1R-trans))-isomer; structure		3.0610
carubicin
Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group.		3.9740anthracycline cation
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		1.9710nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Myelogenous Leukemia
[description not available]		02.8840
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.8840
Experimental Neoplasms
[description not available]		01.9610
Experimental Leukemia
[description not available]		02.8810
Acute Disease
Disease having a short and relatively severe course.		02.8810
Bone Marrow Diseases
Diseases involving the BONE MARROW.		02.3620
Carcinoma, Epidermoid
[description not available]		01.9610
Cancer of Head
[description not available]		01.9610
Benign Neoplasms
[description not available]		03.5730
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		01.9610
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		01.9610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5730
Leukocytopenia
[description not available]		01.9610
Cancer of Lung
[description not available]		01.9610
Thrombopenia
[description not available]		01.9610
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9610
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		01.9610
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9610
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		01.9510
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9610
Leukemia L 1210
[description not available]		01.9510
Di Guglielmo Disease
[description not available]		02.3720
Leukemia, Erythroblastic, Acute
A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.		02.3720